Kylin Therapeutics Inc had been biotechnology company with ties to Purdue University, employing a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. The platform offered the potential of meeting the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform seemed to have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies but by mid-2012, the firm had ceased operations
